Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 388

Sort by

Sort Order Select

Journal Articles

Incidence and prognosis of clonal hematopoiesis in patients with chronic idiopathic neutropenia

Grigorios Tsaknakis, Anna Gallì, Stavros Papadakis, Peggy Kanellou, Chiara Elena, Gabriele Todisco, Elisa Bono, Ettore Rizzo, Elisabetta Molteni, Irene Fragiadaki, Irene Mavroudi, Charalampos Pontikoglou, Anastasios Batas, Stella Maxouri, Emmanouela Linardaki, Nektarios Tavernarakis, Luca Malcovati, Helen A. Papadaki

Blood (2021) 138 (14): 1249–1257.

https://doi.org/10.1182/blood.2021010815

Published: 2021

Includes: Supplemental data

Journal Articles

Chronic lymphoproliferative disorder of NK cells with TNFAIP3 and DNMT3A mutations

Philip L. Bulterys, Oscar Silva

Blood (2021) 137 (24): 3460.

https://doi.org/10.1182/blood.2021011812

Published: 2021

Journal Articles

Modeling and targeting of erythroleukemia by hematopoietic genome editing

Blood (2021) 137 (12): 1628–1640.

https://doi.org/10.1182/blood.2020009103

Published: 2021

Includes: Supplemental data

Journal Articles

Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis

Xiaotian Zhang, Xinyu Wang, Xue Qing David Wang, Jianzhong Su, Nagireddy Putluri, Ting Zhou, Ying Qu, Mira Jeong, Anna Guzman, Carina Rosas, Yun Huang, Arun Sreekumar, Wei Li, Margaret A. Goodell

Blood (2020) 135 (11): 845–856.

https://doi.org/10.1182/blood.2019003330

Published: 2020

Includes: Supplemental data

Journal Articles

Co-occurrence of DNMT3A , NPM1 , FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis

Blood (2020) 135 (11): 870–875.

https://doi.org/10.1182/blood.2019003339

Published: 2020

Includes: Supplemental data

Journal Articles

Lncrna Morrbid Regulates Myeloid Cell Survival of AML Driven By a Combination of FLT3ITD and Epigenetic Mutations

Zhigang Cai, PhD, Baskar Ramdas, PhD, Jonathan Kotzin, Martin P. Carroll, MD, Gerald Wertheim, MD, PhD, Adam Williams, Jorge Henao-Mejia, Reuben Kapur, PhD

Blood (2019) 134 (Supplement_1): 915.

https://doi.org/10.1182/blood-2019-130653

Published: 2019

Journal Articles

Worse Outcomes in Males with MPN Are Associated with Qualitative and Quantitative Differences in Non-Driver Mutational Burden

Theodoros Karantanos, MD PhD, Evan M Braunstein, MD PhD, Shruti Chaturvedi, MBBS, MS, Jerry L. Spivak, MD, Linda Resar, MD, Styliani Karanika, MD, Donna Marie Williams, PhD, Christopher D Gocke, MD, Alison R. Moliterno, MD

Blood (2019) 134 (Supplement_1): 837.

https://doi.org/10.1182/blood-2019-125393

Published: 2019

Journal Articles

Infection Is a Driver of Dnmt3a-Mutant Clonal Hematopoiesis

Daniel Hormaechea Agulla, PhD, Katie A Matatall, PhD, Duy Le, PhDcandidate, Bailee Nicole Kain, PhDcandidate, Roman Jaksik, PhD, Marek Kimmel, PhD DSc, Grant Challen, PhD, Katherine Y. King, MD PhD

Blood (2019) 134 (Supplement_1): 817.

https://doi.org/10.1182/blood-2019-126831

Published: 2019

Journal Articles

PPM1D and DNMT3A Mutations in Myelodysplasia and Clonal Hematopoiesis

Blood (2019) 134 (Supplement_1): 1709.

https://doi.org/10.1182/blood-2019-122032

Published: 2019

Journal Articles

DNMT3A wt NPM1-Mutation Defines a Subgroup of MDS with Special Favorable Outcomes Towards Decitabine Therapy

Lingyun Wu, MD PhD, Xiao Li, MD, Feng Xu, He Qi, Zheng Zhang, Dong Wu, Luxi Song, MD, Liyu Zhou, Chao Xiao, Jiying Su, Juan Guo, Chunkang Chang

Blood (2019) 134 (Supplement_1): 1724.

https://doi.org/10.1182/blood-2019-124008

Published: 2019

Journal Articles

Cell-Extrinsic Stressors from the Aging Bone Marrow (BM) Microenvironment Promote Dnmt3a -Mutant Clonal Hematopoiesis

Jennifer Myers SanMiguel, PhD, Matthew Loberg, BA, Sarah Heuer, Tim Stearns, Kira Young, PhD, Jennifer Trowbridge, PhD

Blood (2019) 134 (Supplement_1): 5.

https://doi.org/10.1182/blood-2019-124511

Published: 2019

Journal Articles

A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML) Using Artificial Intelligence

Blood (2019) 134 (Supplement_1): 2091.

https://doi.org/10.1182/blood-2019-128066

Published: 2019

Journal Articles

Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI)

Nathan Radakovich, BA, Mikkael A. Sekeres, MD MS, Cameron Beau Hilton, BA, Sudipto Mukherjee, MD PhD MPH, Jacob Shreve, MD MS, Yazan Rouphail, Rachel Shirley, Vera Adema, PhD, Hassan Awada, MD, Anjali S. Advani, MD, Cassandra M Kerr, MS, Yasunobu Nagata, MD PhD, Yihong Guan, PhD, Teodora Kuzmanovic, BA, Metis Hasipek, PhD, Babal K. Jha, PhD, Jaroslaw P. Maciejewski, MD PhD, Aziz Nazha, MD

Blood (2019) 134 (Supplement_1): 2089.

https://doi.org/10.1182/blood-2019-126275

Published: 2019

Journal Articles

Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features

Yasunobu Nagata, MD PhD, Hideki Makishima, MD PhD, Cassandra M Kerr, MS, Bhumika J. Patel, MD, Hassan Awada, Vera Adema, PhD, Valeria Visconte, PhD, Sudipto Mukherjee, MD PhD MPH, Thomas Laframboise, PhD, Aziz Nazha, MD, Tomas Radivoyevitch, PhD, Mikkael A. Sekeres, MD MS, Seishi Ogawa, MD PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 2992.

https://doi.org/10.1182/blood-2019-128893

Published: 2019

Journal Articles

SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome

Rami S. Komrokji, MD, David A Sallman, MD, Najla Al Ali, M.Sc, Andrew T Kuykendall, MD, Chetasi Talati, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD, Eric Padron, MD, Alan F. List, MD

Blood (2019) 134 (Supplement_1): 3001.

https://doi.org/10.1182/blood-2019-127462

Published: 2019

Journal Articles

Single Cell Profiling of DNMT3A-Mutant Progenitors Reveals LY86 As a Novel Pre-Leukemia Marker and Potential Therapeutic Target

Mira Jeong, PhD, Sangbae Kim, PhD, Yumei Li, PhD, Rui Chen, PhD, Premal Lulla, MBBS, Margaret Goodell, PhD

Blood (2019) 134 (Supplement_1): 2724.

https://doi.org/10.1182/blood-2019-123597

Published: 2019

Journal Articles

Improved Anti-Leukemic Pre-Clinical Efficacy of a Protac Based MDM2 Degrader in a Large AML Cohort

Malathi Kandarpa, PhD, Luke F. Peterson, PhD, Harish Potu, PhD, Megha Ramappan, Yihong Liu, Avery Polk, Shaomeng Wang, PhD, Moshe Talpaz, MD

Blood (2019) 134 (Supplement_1): 2670.

https://doi.org/10.1182/blood-2019-131949

Published: 2019

Journal Articles

DNMT3A with Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks

Kartika Venugopal, MS, Daniil E Shabashvili, PhD, Jianping Li, MD, Luisa M Posada, Richard Lynn Bennett, PhD, Yang Feng, MS, Daphne Dupere Richer, PhD, Alberto Riva, PhD, Santhi Pondugula, PhD, Jonathan E. Bird, PhD, Jonathan D. Licht, MD, Olga A Guryanova, MD PhD

Blood (2019) 134 (Supplement_1): 535.

https://doi.org/10.1182/blood-2019-128213

Published: 2019

Journal Articles

Dnmt3a Mutation Confers a Selective Advantage Specifically to Cells within the Long-Term Hematopoietic Stem Cell (LT-HSC) Compartment

Elizabeth Eudy, BS, Matthew Loberg, BA, Rebecca Bell, BA, Tim Stearns, Jennifer Trowbridge, PhD

Blood (2019) 134 (Supplement_1): 448.

https://doi.org/10.1182/blood-2019-124540

Published: 2019

Journal Articles

Genetic Vulnerabilities of DNMT3A R882H in Myeloid Malignancies

Malgorzata Gozdecka, PhD, Monika Dudek, MSc, Konstantinos Tzelepis, Aristi Damaskou, MSc, Vijay Baskar, PhD, Penny Wright, Graham Duddy, Eshwar Meduri, PhD, Milena Mazan, PhD, Kosuke Yusa, PhD, Brian J. P. Huntly, PhD MRCP, MB, FRCPath, George S. Vassiliou, FRCPath, MRCP, PhD

Blood (2019) 134 (Supplement_1): 111.

https://doi.org/10.1182/blood-2019-126505

Published: 2019

NARROW

Incidence and prognosis of clonal hematopoiesis in patients with chronic idiopathic neutropenia

Chronic lymphoproliferative disorder of NK cells with TNFAIP3 and DNMT3A mutations

Modeling and targeting of erythroleukemia by hematopoietic genome editing

Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis

Co-occurrence of DNMT3A , NPM1 , FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis

Lncrna Morrbid Regulates Myeloid Cell Survival of AML Driven By a Combination of FLT3ITD and Epigenetic Mutations

Worse Outcomes in Males with MPN Are Associated with Qualitative and Quantitative Differences in Non-Driver Mutational Burden

Infection Is a Driver of Dnmt3a-Mutant Clonal Hematopoiesis

PPM1D and DNMT3A Mutations in Myelodysplasia and Clonal Hematopoiesis

DNMT3A wt NPM1-Mutation Defines a Subgroup of MDS with Special Favorable Outcomes Towards Decitabine Therapy

Cell-Extrinsic Stressors from the Aging Bone Marrow (BM) Microenvironment Promote Dnmt3a -Mutant Clonal Hematopoiesis

A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML) Using Artificial Intelligence

Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI)

Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features

SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome

Single Cell Profiling of DNMT3A-Mutant Progenitors Reveals LY86 As a Novel Pre-Leukemia Marker and Potential Therapeutic Target

Improved Anti-Leukemic Pre-Clinical Efficacy of a Protac Based MDM2 Degrader in a Large AML Cohort

DNMT3A with Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks

Dnmt3a Mutation Confers a Selective Advantage Specifically to Cells within the Long-Term Hematopoietic Stem Cell (LT-HSC) Compartment

Genetic Vulnerabilities of DNMT3A R882H in Myeloid Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only